NICE widens access to Alexion’s Strensiq
Alexion Pharma and the National Institute for Health and Care Excellence have come to a new arrangement that widens NHS access to Strensiq for people with paediatric-onset hypophosphatasia.
Read More
Tag: hypophosphatasia
NICE restricts NHS access to Alexion’s £366K-a-year bone drug
The National Institute for Health and Care Excellence has published draft guidelines that restrict the use of Alexion’s £366,912-a-year enzyme replacement therapy Strensiq by the National Health Service in treating patients with hypophosphatasia.
Read More
NICE backs restricted use of Alexion’s Strensiq
Cost regulators for NHS treatments in England and Wales have recommended use of Alexion’s Strensiq to treat a rare and often fatal condition called hypophosphatasia (HPP), but have restricted its reach to children with certain forms of the condition.
Read More
- Ipsen announces new data on Dysport in neurological disease
- PMGroup Worldwide Ltd welcomes MAD World Summit
- Argenx receives review from FDA for VYVGART in seronegative gMG
- Nuclera extends Series C funding to advance antibody engineering
- Cellistic launches new iPSC-based platforms to expand immuno-oncology therapies
